Trimax Biosciences achieves EDQM Certificate of Suitability for Metformin Hydrochloride
Sigachi Industries announced that Trimax Biosciences, a Sigachi Group Company has successfully achieved the Certificate of Suitability (CEP) for Metformin Hydrochloride from European Directorate for the Quality of Medicines & Health Care (EDQM). This milestone paves the way for Trimax to export this crucial Active Pharmaceutical Ingredient (API) to Europe and other CEP-accepting markets, further strengthening Sigachi's presence in highly regulated pharmaceutical markets. Powered by Capital Market - Live News
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
4 hours ago
- Economic Times
US stocks open higher as investors focus on trade, key jobs data
Synopsis U.S. stock indexes opened higher on Thursday after signs of tariff negotiations between the U.S. and China, while investors looked ahead to a key jobs report to gauge the health of the labor market amid trade uncertainties. Nikita Papers IPO opens on May 27, price band set at Rs 95-104 per share Nikita Papers IPO opens on May 27, price band set at Rs 95-104 per share Why gold prices could surpass $4,000: JP Morgan's bullish outlook explained Why gold prices could surpass $4,000: JP Morgan's bullish outlook explained Cyient shares fall over 9% after Q4 profit declines, core business underperforms Cyient shares fall over 9% after Q4 profit declines, core business underperforms L&T Technology Services shares slide 7% after Q4 profit dips L&T Technology Services shares slide 7% after Q4 profit dips Trump-Powell standoff puts U.S. Rate policy in crosshairs: Who will blink first? Trump-Powell standoff puts U.S. Rate policy in crosshairs: Who will blink first? SEBI warns of securities market frauds via YouTube, Facebook, X and more SEBI warns of securities market frauds via YouTube, Facebook, X and more API Trading for All: Pi42 CTO Satish Mishra on How Pi42 is Empowering Retail Traders API Trading for All: Pi42 CTO Satish Mishra on How Pi42 is Empowering Retail Traders Security, transparency, and innovation: What sets Pi42 apart in crypto trading Security, transparency, and innovation: What sets Pi42 apart in crypto trading Bitcoin, Ethereum, or Altcoins? How investors are structuring their crypto portfolios, Avinash Shekhar explains Bitcoin, Ethereum, or Altcoins? How investors are structuring their crypto portfolios, Avinash Shekhar explains The rise of Crypto Futures in India: Leverage, tax efficiency, and market maturity, Avinash Shekhar of Pi42 explains NEXT STORY
Business Standard
3 days ago
- Business Standard
Sigachi Industries consolidated net profit declines 11.77% in the March 2025 quarter
Sales rise 23.12% to Rs 128.20 crore Net profit of Sigachi Industries declined 11.77% to Rs 13.27 crore in the quarter ended March 2025 as against Rs 15.04 crore during the previous quarter ended March 2024. Sales rose 23.12% to Rs 128.20 crore in the quarter ended March 2025 as against Rs 104.13 crore during the previous quarter ended March 2024. For the full year,net profit rose 21.65% to Rs 69.56 crore in the year ended March 2025 as against Rs 57.18 crore during the previous year ended March 2024. Sales rose 22.38% to Rs 488.24 crore in the year ended March 2025 as against Rs 398.96 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 128.20104.13 23 488.24398.96 22 OPM % 22.2815.69 - 20.4819.21 - PBDT 27.4120.70 32 108.0980.57 34 PBT 22.6717.21 32 92.3269.77 32 NP 13.2715.04 -12 69.5657.18 22
Hans India
4 days ago
- Hans India
Sigachi Industries reports 21 pc drop in net profit in Q4, revenue also declines
Sigachi Industries Limited has announced that the company's net profit fell by approximately 21.16 per cent, coming down to Rs 16.17 crore in Q4 from Rs 20.51 crore in the previous quarter. This dip comes alongside a decline in both revenue from operations and total income. Revenue from operations in Q4 stood at Rs 128.2 crore, down from Rs 139.41 crore in the previous quarter -- a fall of about 8.04 per cent. Total income also dropped to Rs 130.39 crore in Q4 compared to Rs 141.43 crore in Q3, marking a 7.81 per cent decrease. Despite the quarter-on-quarter (QoQ) decline, the company remains optimistic about its growth prospects. Commenting on the performance and outlook, Sigachi Industries Managing Director and CEO Amit Raj Sinha said: "FY25 has been a transformative year for Sigachi, marked by robust financial outcomes and strategic expansions across excipients and APIs." "With our Hyderabad API R&D centre going live in Q1 FY26, regulatory approvals flowing in, and global market penetration deepening, we are positioned for sustainable high-margin growth," he said. "Our 36-year legacy and diversified portfolio give us an unmatched advantage to scale operations globally while safeguarding profitability," he added. "The company is expanding its footprint beyond India, the US, and Europe by aggressively entering Latin America, Southeast Asia, and the Middle East through new distribution partnerships and turnkey O&M contracts," Sigachi said in its filing. Sigachi Industries, founded in 1989 and headquartered in Hyderabad, is a manufacturer in the field of pharma excipients, nutraceuticals, and food ingredients. The company is known for its global leadership in the production of microcrystalline cellulose (MCC), with manufacturing facilities in India and subsidiaries operating internationally. The company serves a broad spectrum of industries, including pharmaceuticals, food and beverages, nutraceuticals, and cosmetics.
